Cargando…
POLE/POLD1 mutation in non‐exonuclease domain matters for predicting efficacy of immune‐checkpoint‐inhibitor therapy
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473642/ https://www.ncbi.nlm.nih.gov/pubmed/34586735 http://dx.doi.org/10.1002/ctm2.524 |
| _version_ | 1784575034925252608 |
|---|---|
| author | Chen, Yan‐Xing Wang, Zi‐Xian Yuan, Shu‐Qiang Jiang, Teng‐Jia Huang, You‐Sheng Xu, Rui‐Hua Wang, Feng Zhao, Qi |
| author_facet | Chen, Yan‐Xing Wang, Zi‐Xian Yuan, Shu‐Qiang Jiang, Teng‐Jia Huang, You‐Sheng Xu, Rui‐Hua Wang, Feng Zhao, Qi |
| author_sort | Chen, Yan‐Xing |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8473642 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84736422021-10-01 POLE/POLD1 mutation in non‐exonuclease domain matters for predicting efficacy of immune‐checkpoint‐inhibitor therapy Chen, Yan‐Xing Wang, Zi‐Xian Yuan, Shu‐Qiang Jiang, Teng‐Jia Huang, You‐Sheng Xu, Rui‐Hua Wang, Feng Zhao, Qi Clin Transl Med Letter to Editor John Wiley and Sons Inc. 2021-09-26 /pmc/articles/PMC8473642/ /pubmed/34586735 http://dx.doi.org/10.1002/ctm2.524 Text en © 2021 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letter to Editor Chen, Yan‐Xing Wang, Zi‐Xian Yuan, Shu‐Qiang Jiang, Teng‐Jia Huang, You‐Sheng Xu, Rui‐Hua Wang, Feng Zhao, Qi POLE/POLD1 mutation in non‐exonuclease domain matters for predicting efficacy of immune‐checkpoint‐inhibitor therapy |
| title | POLE/POLD1 mutation in non‐exonuclease domain matters for predicting efficacy of immune‐checkpoint‐inhibitor therapy |
| title_full | POLE/POLD1 mutation in non‐exonuclease domain matters for predicting efficacy of immune‐checkpoint‐inhibitor therapy |
| title_fullStr | POLE/POLD1 mutation in non‐exonuclease domain matters for predicting efficacy of immune‐checkpoint‐inhibitor therapy |
| title_full_unstemmed | POLE/POLD1 mutation in non‐exonuclease domain matters for predicting efficacy of immune‐checkpoint‐inhibitor therapy |
| title_short | POLE/POLD1 mutation in non‐exonuclease domain matters for predicting efficacy of immune‐checkpoint‐inhibitor therapy |
| title_sort | pole/pold1 mutation in non‐exonuclease domain matters for predicting efficacy of immune‐checkpoint‐inhibitor therapy |
| topic | Letter to Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473642/ https://www.ncbi.nlm.nih.gov/pubmed/34586735 http://dx.doi.org/10.1002/ctm2.524 |
| work_keys_str_mv | AT chenyanxing polepold1mutationinnonexonucleasedomainmattersforpredictingefficacyofimmunecheckpointinhibitortherapy AT wangzixian polepold1mutationinnonexonucleasedomainmattersforpredictingefficacyofimmunecheckpointinhibitortherapy AT yuanshuqiang polepold1mutationinnonexonucleasedomainmattersforpredictingefficacyofimmunecheckpointinhibitortherapy AT jiangtengjia polepold1mutationinnonexonucleasedomainmattersforpredictingefficacyofimmunecheckpointinhibitortherapy AT huangyousheng polepold1mutationinnonexonucleasedomainmattersforpredictingefficacyofimmunecheckpointinhibitortherapy AT xuruihua polepold1mutationinnonexonucleasedomainmattersforpredictingefficacyofimmunecheckpointinhibitortherapy AT wangfeng polepold1mutationinnonexonucleasedomainmattersforpredictingefficacyofimmunecheckpointinhibitortherapy AT zhaoqi polepold1mutationinnonexonucleasedomainmattersforpredictingefficacyofimmunecheckpointinhibitortherapy |